Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Karin KozbialStephan MoserRamona Al-ZoairyRemy SchwarzerChristian DatzRudolf StauberHermann LaferlMichael StrasserSandra BeinhardtAlbert F StättermayerMichael GschwantlerHeinz ZollerAndreas MaieronIvo GraziadeiMichael TraunerPetra Steindl-MundaHarald HoferPeter FerenciPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
Eradication of HCV by DAA therapy was durable irrespective of the DAA combination used. Most of the cured patients had an excellent long-term clinical prognosis. Nevertheless, the risk of new occurrence of HCC remains worrisome and thus regular surveillance is obligatory even after clinical stabilization and improvement of the patient.
Keyphrases
- end stage renal disease
- newly diagnosed
- hepatitis c virus
- public health
- risk assessment
- prognostic factors
- case report
- stem cells
- human immunodeficiency virus
- antiretroviral therapy
- hiv infected
- helicobacter pylori infection
- immune response
- patient reported outcomes
- cell therapy
- combination therapy
- smoking cessation